TNFRSF1B and Sezary syndrome: TNFR2 has been considered a novel target for cancer immunotherapy and autoimmune diseases because it is aberrantly expressed by some tumor cells and normal cells including acute myeloid leukemia [37], Sezary syndrome [38], and Treg cells [39,40].